Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Prelude Therapeutics Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $6.500M Up From $3.000M YoY

Author: Benzinga Newsdesk | November 12, 2025 07:06am
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 39.53 percent increase over losses of $(0.43) per share from the same period last year. The company reported $6.500 million in sales this quarter. This is a 116.67 percent increase over sales of $3.000 million the same period last year.

Posted In: PRLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist